SHARPIN and cancer: To examine whether SIPL1 expression correlates with ER+ or PR+ breast cancer, we divided the cancers into a group of strong SIPL1 expression (SIPL1+) and a group of weak SIPL1 expression (SIPL1-) based on an HScore of 40 (see Materials and Methods for justification).